Thymosin-β4: A key modifier of renal disease

Elisavet Vasilopoulou, Paul R. Riley, David A. Long
2018 Expert Opinion on Biological Therapy  
There is an urgent need for new treatments for chronic kidney disease (CKD). Thymosin-b4 is a peptide that reduces inflammation and fibrosis and has the potential to restore endothelial and epithelial cell injury, biological processes involved in the pathophysiology of CKD. Therefore, thymosin-b4 could be a novel therapeutic direction for CKD. Areas covered: Here, we review the current evidence on the actions of thymosin-b4 in the kidney in health and disease. Using transgenic mice, two recent
more » ... tudies have demonstrated that endogenous thymosin-b4 is dispensable for healthy kidneys. In contrast, lack of endogenous thymosin-b4 exacerbates mouse models of glomerular disease and angiotensin-II-induced renal injury. Administration of exogenous thymosin-b4, or its metabolite, Ac-SDKP, has shown therapeutic benefits in a range of experimental models of kidney disease. Expert opinion: The studies conducted so far reveal a protective role for thymosin-b4 in the kidney and have shown promising results for the therapeutic potential of exogenous thymosin-b4 in CKD. Further studies should explore the mechanisms by which thymosin-b4 modulates kidney function in different types of CKD. Ac-SDKP treatment has beneficial effects in many experimental models of kidney disease, thus supporting its potential use as a new treatment strategy.
doi:10.1080/14712598.2018.1473371 pmid:29727205 fatcat:jps4l3qjxfbkxj22mbe64ta5cm